Sanctuary Advisors LLC Makes New $587,000 Investment in BioCryst Pharmaceuticals, Inc. $BCRX

Sanctuary Advisors LLC purchased a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 58,673 shares of the biotechnology company’s stock, valued at approximately $587,000.

Several other hedge funds have also recently bought and sold shares of BCRX. Larson Financial Group LLC lifted its position in shares of BioCryst Pharmaceuticals by 1,188.0% in the fourth quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 3,267 shares in the last quarter. Allworth Financial LP acquired a new stake in shares of BioCryst Pharmaceuticals in the 2nd quarter valued at $52,000. Focus Partners Wealth acquired a new stake in shares of BioCryst Pharmaceuticals in the third quarter worth about $77,000. Envestnet Portfolio Solutions Inc. acquired a new stake in BioCryst Pharmaceuticals in the 4th quarter worth approximately $81,000. Finally, Mercer Global Advisors Inc. ADV bought a new stake in shares of BioCryst Pharmaceuticals during the 3rd quarter worth $81,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ:BCRX opened at $9.82 on Friday. The firm’s 50 day simple moving average is $9.71 and its 200 day simple moving average is $9.05. The company has a market capitalization of $2.51 billion, a price-to-earnings ratio of -6.55 and a beta of 0.55. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $6.00 and a fifty-two week high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The company had revenue of $218.25 million during the quarter, compared to analyst estimates of $183.28 million. During the same quarter in the previous year, the business earned $0.15 EPS. The firm’s revenue was up 33.6% on a year-over-year basis. Equities research analysts expect that BioCryst Pharmaceuticals, Inc. will post -2.25 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on BCRX shares. Weiss Ratings restated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research note on Monday, June 1st. Cantor Fitzgerald lifted their target price on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a research report on Tuesday, June 30th. Wedbush lowered their price target on BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. Finally, Citizens Jmp raised their target price on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a research note on Thursday, May 7th. Eight analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.60.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.